140 related articles for article (PubMed ID: 33624546)
21. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
22. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
[TBL] [Abstract][Full Text] [Related]
23. Lepidic intrapulmonary growth of malignant mesothelioma presenting as recurrent hydropneumothorax.
Wu H; Tino G; Gannon FH; Kaiser LR; Pietra GG
Hum Pathol; 1996 Sep; 27(9):989-92. PubMed ID: 8816899
[TBL] [Abstract][Full Text] [Related]
24. Non-asbestos-related malignant pleural mesothelioma.
Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
[TBL] [Abstract][Full Text] [Related]
25. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
Manur R; Lamzabi I
Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731
[TBL] [Abstract][Full Text] [Related]
26. Pleural neoplastic pathology.
Karpathiou G; Stefanou D; Froudarakis ME
Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
[TBL] [Abstract][Full Text] [Related]
27. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
28. [Pseudomesotheliomatous carcinoma of the lung].
Maeda R; Isowa N; Kawasaki Y; Tokuyasu H; Itakura A; Miura H; Onuma H
Kyobu Geka; 2007 Jul; 60(7):555-8. PubMed ID: 17642217
[TBL] [Abstract][Full Text] [Related]
29. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
30. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
31. Not everything is what it seems: malignant pleural mesothelioma mimicking lung cancer.
Prisciandaro E; Girelli L; Rampinelli C; Ghioni M; Spaggiari L
Adv Respir Med; 2019; 87(6):265-267. PubMed ID: 31970729
[TBL] [Abstract][Full Text] [Related]
32. Malignant mesothelioma masquerading as a multinodular bronchioloalveolar cell adenocarcinoma with widespread pulmonary nodules.
Felner KJ; Wieczorek R; Kline M; Smith RL; Sidhu GS
Int J Surg Pathol; 2006 Jul; 14(3):229-33. PubMed ID: 16959710
[TBL] [Abstract][Full Text] [Related]
33. Plasma cell myeloma presenting with diffuse pleural involvement: a hitherto unreported pattern of a new mesothelioma mimicker.
Colonna A; Gualco G; Bacchi CE; Leite MA; Rocco M; DeMaglio G; Pizzolitto S; Falconieri G
Ann Diagn Pathol; 2010 Feb; 14(1):30-5. PubMed ID: 20123454
[TBL] [Abstract][Full Text] [Related]
34. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes SM; Alrifai D; Fennell DA
N Engl J Med; 2021 Sep; 385(13):1207-1218. PubMed ID: 34551230
[No Abstract] [Full Text] [Related]
36. Presence of malignant mesothelial cells in the sputum.
Choi YH; Park KY; Ryoo BY; Na II; Yang SH; Koh JS; Kim CH; Lee JC
Intern Med; 2008; 47(1):57-60. PubMed ID: 18176007
[TBL] [Abstract][Full Text] [Related]
37. Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma.
Terra SBSP; Roden AC; Aubry MC; Yi ESJ; Boland JM
Arch Pathol Lab Med; 2021 Feb; 145(2):208-213. PubMed ID: 33501493
[TBL] [Abstract][Full Text] [Related]
38. Nucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma.
Masiuk M; Waloszczyk P; Lewandowska M; Dobak E; Urasinska E
Thorac Cancer; 2020 Sep; 11(9):2529-2535. PubMed ID: 32671956
[TBL] [Abstract][Full Text] [Related]
39. Malignant mesothelioma with squamous differentiation.
Tanaka H; Akiyama Y; Kitamura A; Matsumoto N; Tomita M; Kataoka H
Histopathology; 2018 Jun; 72(7):1216-1220. PubMed ID: 29430704
[TBL] [Abstract][Full Text] [Related]
40. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.
Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T
Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
